

Aloran Mazumder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11581235/publications.pdf>

Version: 2024-02-01

17
papers

350
citations

840776

11
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

742
citing authors

#	ARTICLE	IF	CITATIONS
1	The DNA damage repair landscape in Black women with breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210754.	3.2	6
2	Endocannabinoid dysfunction in neurological disease: neuro-ocular DAGLA-related syndrome. <i>Brain</i> , 2022, 145, 3383-3390.	7.6	3
3	Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. <i>Nature Communications</i> , 2021, 12, 2940.	12.8	14
4	HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	2.8	11
5	Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells. <i>Cancer Letters</i> , 2020, 469, 468-480.	7.2	8
6	Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. <i>Clinical Epigenetics</i> , 2020, 12, 69.	4.1	19
7	The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. <i>Pharmacological Research</i> , 2020, 160, 105058.	7.1	7
8	Tetrahydrobenzimidazole TMQ0153 triggers apoptosis, autophagy and necroptosis crosstalk in chronic myeloid leukemia. <i>Cell Death and Disease</i> , 2020, 11, 109.	6.3	21
9	The dialkyl resorcinol stemphol disrupts calcium homeostasis to trigger programmed immunogenic necrosis in cancer. <i>Cancer Letters</i> , 2018, 416, 109-123.	7.2	20
10	Natural scaffolds in anticancer therapy and precision medicine. <i>Biotechnology Advances</i> , 2018, 36, 1563-1585.	11.7	35
11	Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: Involvement of ER stress and DAMP release. <i>Cancer Letters</i> , 2018, 438, 197-218.	7.2	29
12	Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	4
13	Cardiac Glycoside Glucoevatromonoside Induces Cancer Type-Specific Cell Death. <i>Frontiers in Pharmacology</i> , 2018, 9, 70.	3.5	28
14	Discovery and Characterization of <i>N</i> -3-Cyanophenyl- <i>N</i> -(6- <i>tert</i> -butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2 <i>H</i> -1-benzop a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4714-4733.	6.4	22
15	Tubulin-binding anticancer polysulfides induce cell death via mitotic arrest and autophagic interference in colorectal cancer. <i>Cancer Letters</i> , 2017, 410, 139-157.	7.2	21
16	4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90 α chaperone activity against prostate cancer. <i>Biochemical Pharmacology</i> , 2016, 99, 31-52.	4.4	48
17	Discovery and characterization of Isofistularin-3, a marine brominated alkaloid, as a new DNA demethylating agent inducing cell cycle arrest and sensitization to TRAIL in cancer cells. <i>Oncotarget</i> , 2016, 7, 24027-24049.	1.8	54